B O O K - American College of Rheumatology

INVITED SPEAKER /MODERATOR INDEX
P
Paget, Stephen A, MD
Giant Cell Arteritis - Diagnosis
and Therapy . . . . . . . . . . . . . . . . . . 69
Disclosure: Nothing to Disclose
REF Marshall J. Schiff, MD, Memorial
Lectureship: Everything a Rheumatologist
Should Know About Spine Surgery but Was
Afraid to Ask . . . . . . . . . . . . . . . . . . 84
Disclosure: Nothing to Disclose
Paiva, Eduardo S, MD
When Pieces Don’t Fit . . . . . . . . . . . .120
Disclosure: Apsen Brazil, 5; Eli Lilly Brazil, 8;
Pfizer Brazil, 8
Passo, Murray H, MD
Pediatrics: Difficult to Treat Juvenile Idiopathic
Arthritis . . . . . . . . . . . . . . . . . . . . 29
Disclosure: Pfizer, 2, 5
Pennington, Scott D, MD
Total Shoulder Arthroplasty and Reverse Total
Shoulder Arthroplasty: Surgery
and Rehabilitation. . . . . . . . . . . . . . .147
Disclosure: Nothing to Disclose
Perez-Masuelli, Carmen, MD
The Ideal Rheumatology Practice . . . . . .104
Disclosure: Nothing to Disclose
Perlman, Harris R, PhD
Innate Immunity and Inflammation . . . . . 30
Disclosure: Nothing to Disclose
Phillips, Kristine, MD, PhD
Disparities and Pain: Examining Research,
Practice and Policy . . . . . . . . . . . . . . 95
Disclosure: Nothing to Disclose
Interstitial Lung Diseases in the Rheumatic
Diseases . . . . . . . . . . . . . . . . . . . .109
Disclosure: Nothing to Disclose
Pierangeli, Silvia S, PhD
Antiphospholipid Syndrome . . . . . . . . . 87
Disclosure: Nothing to Disclose
Pillai, Shiv, MD, PhD
Session I: B cell Development . . . . . . . . 20
Disclosure: Nothing to Disclose
Pincus, Theodore, MD
WK - Patient Questionnaires to Monitor Status
and Document Improvement in Standard Care:
Practical Considerations . . . . . . . . . . .102
Disclosure: Nothing to Disclose
Clinical Research Methodology . . . . . . .107
Disclosure: Nothing to Disclose
Pisetsky, David S, MD, PhD
From Fat to Joints - The Vicious Side of
Adipokines . . . . . . . . . . . . . . . . . . . 98
Disclosure: Nothing to Disclose
Plaas, Anna H, PhD
Molecular Mechanisms of Inflammatory
Signaling in Cartilage Destruction . . . . . . 27
Disclosure: Pfizer, 2; Smith Nephew, 2
Osteoarthritis . . . . . . . . . . . . . . . . .110
Disclosure: Pfizer Inc, 2; Smith Nephew, 2
Plass, Nicole D, BSN, MPA
The Multidisciplinary Approach to Hereditary
Periodic Fever Syndromes . . . . . . . . . . 58
Disclosure: Nothing to Disclose
Pollock, P. Scott MD
Musculoskeletal Ultrasound Course for
Rheumatologists - Day One. . . . . . . . . . 17
Disclosure: TBA
Musculoskeletal Ultrasound Course for
Rheumatologists - Day Two. . . . . . . . . . 22
Disclosure: TBA
Poole, Janet L, PhD, OTR
Adaptations and Solutions to Help People with
Scleroderma Continue to Work . . . . . . .102
Disclosure: American College of Rheumatology
Research Education Foundation, 2
Measure by Measure: Assessing Psychological
Health and Well-Being in Scleroderma . . .135
Disclosure: American College of Rheumatology
Research Education Foundation, 2
Practice Potpourri . . . . . . . . . . . . . . . 86
Disclosure: American College of Rheumatology
Research Education Foundation, 2
ARHP General Session I - Keynote
Address. . . . . . . . . . . . . . . . . . . . . 32
Disclosure: American College of Rheumatology
Research Education Foundation, 2
ARHP General Session II: ARHP Distinguished
Lecturer . . . . . . . . . . . . . . . . . . . . 62
Disclosure: American College of Rheumatology
Research Education Foundation, 2
Moderators Orientation . . . . . . . . . . . 27
Disclosure: American College of Rheumatology
Research Education Foundation, 2
Pope, Janet E, MD, MPH
Raynaud’s and Digital Ischemia . . . . 65, 105
Disclosure: Actelion, 2, 5; Mediquest, 5; Pfizer,
5; UT, 2
Pope, Richard M, MD
Toll-like Receptors and Inflammation: Towards
Innovative Treatment of Rheumatoid Arthritis
. . . . . . . . . . . . . . . . . . . . . . . . . 38
Disclosure: Nothing to Disclose
Porter, Duncan, MD
Rheumatoid Arthritis Treatment 2010:
Traditional DMARDs, Biologic DMARDs and
Newer Treatment Strategies . . . . . . . . 114
Disclosure: Abbott, 5, 8; Pfizer, 2; Roche, 2, 5;
Schering Plough, 5, 8; UCB, 5; Wyeth, 2
Pruijn, Ger, PhD
The Biology of Citrullination . . . . . . . . . 68
Disclosure: Nothing to Disclose
R
Radbruch, Andreas H, PhD
Session II: B cell Activation and
Trafficking . . . . . . . . . . . . . . . . . . . 20
Disclosure: Nothing to Disclose
Radstake, Timothy RDJ, MD, PhD
Toll-like Receptors and Inflammation: Towards
Innovative Treatment of Rheumatoid Arthritis
. . . . . . . . . . . . . . . . . . . . . . . . . 38
Disclosure: Nothing to Disclose
Scleroderma-Biomarkers . . . . . . . . . . 111
Disclosure: Nothing to Disclose
Randall, Troy, PhD
Session III: B cells in the Immune Response. 23
Disclosure: Vaccinex, 2
Rapoff, Michael A, PhD
Daltroy Memorial Lecture: Adherence to
Medical Regimens for Rheumatic Diseases
and the Importance of Patient-Clinician
Communication . . . . . . . . . . . . . . . . 61
Disclosure: Nothing to Disclose
ARHP Networking at Noon . . . . . . . . . . 63
Disclosure: Nothing to Disclose
Rawlings, David J, MD
Session II: B cell Activation and Trafficking . 20
Disclosure: Nothing to Disclose
Ray, Laura E, MA, MLS
Web-based Support of Clinical Practice and
Teaching: Twittering, Blogging, and Doing the
Wiki. . . . . . . . . . . . . . . . . . . . . . .120
Disclosure: Nothing to Disclose
ARHP Networking at Noon . . . . . . . . . . 64
Disclosure: Nothing to Disclose
Raza, Karim, BA, PhD
The Preclinical Stage of Rheumatoid Arthritis:
Towards Prevention of Disease? . . . . . . . 76
Disclosure: Cellzome, 2; UCB, 2, 5; Wyeth, 2
Reed, Ann M, MD
Juvenile Dermatomyositis in 2010 - From Bench
to Bedside . . . . . . . . . . . . . . . . . . . 31
Disclosure: Nothing to Disclose
Reiff, Andreas O, MD
Inflammatory Eye Disease . . . . . . . . . . 35
Disclosure: AMGEN, PFIZER, ABBOTT, MERCK, 8
Integrating Immunology and Biologics into
Clinical Practice . . . . . . . . . . . . . . . . 26
Disclosure: AMGEN, PFIZER, ABBOTT, MERCK, 8
Richardson, Bruce C, MD, PhD
The Revolution of Epigenetics in
Autoimmunity . . . . . . . . . . . . . . . . . 47
Disclosure: Nothing to Disclose
Rider, Lisa G, MD
Practice Potpourri . . . . . . . . . . . . . . . 86
Disclosure: Nothing to Disclose
Myositis . . . . . . . . . . . . . . . . . . . .110
Disclosure: Nothing to Disclose
Ridley, David J, MD
The Ideal Rheumatology Practice . . . . . .104
Disclosure: BMS, 2; Celgene, 2; Centacor, 2;
Genentech, 2; UCB, 2
Rigby, William F. C, MD
ACR REF Within Our Reach: Finding a Cure for
Rheumatoid Arthritis . . . . . . . . . . . . . 45
Disclosure: Nothing to Disclose
Riskind, Peter, MD, PhD
Update on Multiple Sclerosis. . . . . . . . . 59
Disclosure: Biogen idec, 5; Teva, 5, 9
Rock, Kenneth L, MD
Cell Death: Receptors, Sensors and
Inflammatory Pathways. . . . . . . . . . . .114
Disclosure: Sanofi-Aventis, 2
Roediger, Joan M, JD, LLM
Contract Negotiations for Physicians . . . . 65
Disclosure: Nothing to Disclose
310
2010 Program Book